tradingview.comSEP 242 min read$MMED

MiniMed a new Buy at Truist on turnaround following Medtronic split

Truist initiated a Buy rating for MiniMed (MMED) with a $29 price target, citing improved investment, strategy, and new product launches. The company, spun off from Medtronic (MDT), is expected to maintain and grow its market share in insulin-intensive diabetes segments. Truist forecasts 10% revenue growth and potential EPS doubling in two years.

Original reporting

tradingview.com

Published Sep 24, 2026, 4:53 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 24, 2026, 5:34 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

MiniMed a new Buy at Truist on turnaround following Medtronic split — source image — Source · tradingview.com

Decision brief

The 30-second read

$MMEDBullishHigh

Why it matters

Analyst upgrade could attract new institutional interest and drive short‑term price appreciation.

Market read

First‑report analyst upgrade provides a fresh catalyst for MiniMed's stock.

What to watch

Potential regulatory delays for new CGM devices could temper upside.

Relevance 7/10Novelty 7/10Timing: today

Background

MiniMed Group recently spun off from Medtronic and is seeking growth through product launches and partnerships.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MMEDBullishHigh confidence

Context

Truist initiated a Buy rating with a $29 price target, citing recent strategic improvements and new product launches.

Expected impact

Potential 30-40% rally if target is achieved.

Evidence & confidence

Buy rating and 41% upside target provide a clear actionable catalyst.

Market effects

Sector

May boost sentiment for diabetes device sector and related suppliers.

Regional

Limited to US biotech/medical device markets.

Global

Minor, primarily affects MiniMed and peers.

Counterpoint

What could challenge this read

Skeptics may question Medtronic's retained 90% stake and execution risk of spin‑off.

Key entities

Analyst
Truist
Issued the Buy rating and $29 price target.
Partner
Abbott Laboratories
Partnered with MiniMed on CGM technology.

Read at source ← All news

SEP 25

$MDTMed

[425] Medtronic plc Business Combination Communication

Medtronic (MDT) is offering shareholders, including employees in its 401(k) plans, the option to exchange MDT shares for MiniMed (MMED) shares at a 7% discount. The exchange offer, part of MiniMed's planned separation, allows for up to 225.4 million MMED shares to be exchanged. Participants must decide by October 5, 2026, with a final exchange ratio to be announced later.

stocktitan.net2 min

SEP 24

$MDTMedAI 8/10

Could Medtronic (MDT)’s $700 Million Robotics Bet Unlock its Next Growth Engine?

Medtronic (MDT) announced a $700 million partnership with Cornerstone Robotics to distribute its Sentire surgical system in Europe, China, and Singapore. Medtronic will co-distribute Sentire with its Hugo system, aiming to expand its robotic-assisted surgery offerings. The deal targets diverse hospital budgets and accelerates market penetration in high-margin robotic surgery, though it introduces capital allocation and execution risks.

insidermonkey.com2 min

SEP 24

$AAPLLow

Tech giant Apple continues to dominate Irish Top 1,000 rankings with €209bn in revenue

Apple led The Irish Times' Top 1,000 rankings with €209.3bn revenue and €72bn profit. Microsoft, Meta, and Google followed. Eli Lilly entered the top 10. CRH was the largest indigenous company. Apple and Meta reduced Irish headcounts. Irish corporation taxes surged due to tech profits.

irishtimes.com3 min

SEP 21

$MDTHighAI 9/10

Medtronic Expands Surgical Robotics Portfolio in $700 Million Cornerstone Partnership

Medtronic invested $700M in Cornerstone Robotics to expand its surgical robotics portfolio, adding the Sentire system. The deal grants Medtronic distribution rights in select markets. Medtronic also completed a $650M acquisition of SPR Therapeutics for pain management and a $550M acquisition of Scientia Vascular for neurovascular technology.

thehealthcaretechnologyreport.com2 min

SEP 18

$MDTMedAI 8/10

Two Catalysts for Medtronic: Surgical Robots and Dividend King Run

Medtronic (MDT) shares have fallen 3% YTD but attract investors due to Hugo robotic surgery system growth and dividend increases. Hugo gained FDA clearance for urology and filed for broader use. Q1 FY2027 revenue rose 13.7% to $9.8B, EPS up 40.7% to $1.14. Guidance raised: organic revenue growth now 7.25-7.75%, GAAP EPS $5.94-$6.00. Dividend raised 1.4% to $0.72, nearing 'Dividend King' status. Trades at 22x trailing earnings, 15x forward earnings.

nai500.com3 min

SEP 17

$MDTHighAI 8/10

Medtronic Advances Diabetes Spin

Medtronic (MDT) launched an exchange offer for up to 225,361,295 MiniMed Group Inc. shares, part of its diabetes business separation. It corrected a prospectus error regarding the guaranteed delivery period for tender documentation, which now expires at 5:00 p.m. NY time on the second NYSE trading day after execution.

tipranks.com1 min